ATP6V0D2

Across TCGA pan-cancer cohorts, ATP6V0D2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ATP6V0D2 data layer compared with 28 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ATP6V0D2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ATP6V0D2 expression acts as an unfavorable survival marker, although some lineages such as LUSC and UCEC show a favorable association.

LIHC, LUSC, and SKCM are the cancer types where ATP6V0D2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.118	0.707	<.001	18	view →
LUSC	DFS	Median	All	1.000	0.383	.033	4	view →
SKCM	DFS	Median	III,IV	0.015	0.648	<.001	3	view →
UCEC	OS	Median	All	0.953	0.644	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ATP6V0D2–LIHC (OS)

Open the LIHC breakdown →